Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. - Wikidata - wikimedia - TriplyDB

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.

http://www.wikidata.org/entity/Q34387974

about

Targeting stromal microenvironment in pancreatic ductal adenocarcinoma: controversies and promises Fibroblasts, an inconspicuous but essential player in colon cancer development and progression Targeting inflammation in pancreatic cancer: Clinical translation Molecular therapeutics in pancreas cancer From bench to bedside a comprehensive review of pancreatic cancer immunotherapy.Genetics and biology of pancreatic ductal adenocarcinoma Viro-immune therapy: A new strategy for treatment of pancreatic cancer GEMMs as preclinical models for testing pancreatic cancer therapies Perspectives in the treatment of pancreatic adenocarcinoma Real-Time Imaging of Resident T Cells in Human Lung and Ovarian Carcinomas Reveals How Different Tumor Microenvironments Control T Lymphocyte Migration Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma The application of the fibroblast activation protein α-targeted immunotherapy strategy PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations Carcinoma-associated fibroblasts: orchestrating the composition of malignancy Crosstalk between cancer cells and blood endothelial and lymphatic endothelial cells in tumour and organ microenvironment Concise Review: Stem Cells in Pancreatic Cancer: From Concept to Translation Exploring the tumor microenvironment with nanoparticles Utilizing past and present mouse systems to engineer more relevant pancreatic cancer models From mice to humans: developments in cancer immunoediting T cell exclusion, immune privilege, and the tumor microenvironment The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1.Inflammatory cell distribution in primary merkel cell carcinoma.Stromal reengineering to treat pancreas cancer Stroma-derived Fibrinogen-like Protein 2 Activates Cancer-associated Fibroblasts to Promote Tumor Growth in Lung Cancer Chemotherapy and tumor microenvironment of pancreatic cancer.Pancreatic cancer, inflammation, and microbiome.Fibroblast heterogeneity in the cancer wound.Immunology of naturally transmissible tumours.Fibroblastic reticular cells of the lymph node are required for retention of resting but not activated CD8+ T cells.Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008 Organoid models of human and mouse ductal pancreatic cancer Big opportunities for small molecules in immuno-oncology.CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients.Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression.Molecular pathways: myeloid complicity in cancer.New horizons in tumor microenvironment biology: challenges and opportunities Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.Cancer-associated fibroblasts from lung tumors maintain their immunosuppressive abilities after high-dose irradiation.Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells.

P2860

Q26747140-0B0872FA-9C05-49F3-AF47-C5CE1889D882 Q26747341-60558138-952F-44AC-9456-3F227253CCF9 Q26751686-953FCCA0-411F-4F99-A2E6-2941DA189166 Q26751709-6D2C6313-612C-440D-BA55-39EDBEFE27A3 Q26765123-2ED6DCF2-B486-4C15-9D0B-8511CC5FF556 Q26765438-5056E072-B9F7-491A-9E04-D4AFDC4CFCD9 Q26774641-803D22AE-9EFC-47C5-8246-7E940FABD37B Q26781848-49383D9B-F179-4E00-8275-DA431916689E Q26797248-5BFF551C-6538-4FD3-BCCC-E91E0BF336AA Q27329768-80F1623F-E2A8-45C6-BB6F-85503BACB824 Q28069864-84319AB6-E0DD-4678-B335-B230E133E32C Q28073437-F8C4201E-FB36-4283-90AF-A7BFC9827EC2 Q28075712-E191A425-45A1-473B-9B60-9FE0E55010C0 Q28078667-8557784E-473D-41AD-B0DD-F8235B5204F6 Q28081431-63197591-F410-4EE8-A9A7-EE371C0BC0BA Q28081553-B31014AF-F25F-4602-AC6A-6EDC6272A69D Q28082374-140437EC-68B6-4EFC-82C7-271F8825111C Q28083091-327AB11C-4C5B-4830-9E6A-95DD8304FA81 Q28088304-89265D0E-EA90-452A-A318-20FCECA28B07 Q28259872-CFB6E604-9C3F-4DF4-978C-75E3A11A2BAD Q33591618-1E2807AC-BAE8-4B07-8E9D-549AA165413C Q33820294-50C0F780-20C7-4CC4-9E26-5E64DE86CC8B Q33827708-728DF189-16B6-4AF9-B6CA-EE1A8333E283 Q33837289-E83947EC-C774-4BC8-B666-6BD0A7C0877C Q33876637-2FD51E28-70CC-4757-9939-AFCFC485E71B Q33956107-847430FE-5234-4AAE-9BC2-051A5E4D209B Q33964324-AD7A2F6C-EA1A-4C36-A744-1E49828251FF Q34041901-9938F4FB-5487-4C67-BE39-EF687D80D0D0 Q34082904-AFB72A9C-6E3D-4DB5-A98E-46F343BBBF98 Q34306503-98440A63-3619-49CD-895D-5D48E0882BA4 Q34456438-E6C0F30B-BC6F-4521-982D-ABC049D6C2F8 Q34487689-FBC848E2-C3C8-411F-856B-2065BE2ADF3F Q34535488-914B260A-F943-4E88-8D1D-C0986CFBB298 Q34539323-3A7EF71A-9437-4757-9F0A-37BA66108475 Q34725969-2C47BE31-EDA0-4274-8E1E-18D86CBF3B25 Q35151324-13D631D8-D2C1-4B2E-8CAC-B60A6443023A Q35329190-22EC9B70-DA04-4503-BE85-77D79C39B834 Q35598951-ADD197E3-A280-4ADB-8F10-BC8CCDC63D14 Q35772377-F3F4797B-2BFD-4E68-B49D-E85A723201FD Q35862799-C5751C66-02FC-46A0-9E4A-5359AD4EEFB4

P2860

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.

http://www.wikidata.org/entity/Q34387974

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

name

Targeting CXCL12 from FAP-expr ...... otherapy in pancreatic cancer.

@ast

Targeting CXCL12 from FAP-expr ...... otherapy in pancreatic cancer.

@en

Targeting CXCL12 from FAP-expr ...... otherapy in pancreatic cancer.

@nl

type

label

Targeting CXCL12 from FAP-expr ...... otherapy in pancreatic cancer.

@ast

Targeting CXCL12 from FAP-expr ...... otherapy in pancreatic cancer.

@en

Targeting CXCL12 from FAP-expr ...... otherapy in pancreatic cancer.

@nl

prefLabel

Targeting CXCL12 from FAP-expr ...... otherapy in pancreatic cancer.

@ast

Targeting CXCL12 from FAP-expr ...... otherapy in pancreatic cancer.

@en

Targeting CXCL12 from FAP-expr ...... otherapy in pancreatic cancer.

@nl

P1433

Q34387974-BE31C53B-6BB1-432B-B1CC-041D1BE74F3C

P1476

Q34387974-5096BDE7-D7D5-4E5C-BE24-A6249C71015D

P2093

Q34387974-15137795-BD7F-4E6F-A014-48C18428FF04

Q34387974-335368CB-6CD0-495D-BEF2-6547ECEF5030

Q34387974-71712ED9-51F2-4C01-A30A-3B57717CC333

Q34387974-76CFE1AC-60E8-4A9D-B740-B92FE44D8C91

Q34387974-83BFCC03-71AF-40A4-B8B7-42A959CFF92C

Q34387974-89E4DD94-D9D8-4E9E-BA40-D6448B3ABCC7

Q34387974-ADF09929-BD82-49DB-BB7D-B90225C422EF

Q34387974-C93B1AF1-2FA0-4BC0-9509-6ADBB644A46A

Q34387974-F2798877-EF40-4D04-96AC-BD759858008B

Q34387974-FA6745B4-A859-4E25-8502-0173CADE147E

P2860

Q34387974-051B8870-2041-4612-8F23-338A42A09807

Q34387974-085052B5-ECB1-48CF-B91E-BC5783080204

Q34387974-0F3F977D-74AF-4D7A-A5BC-F9F36A5BADD9

Q34387974-12D6078F-29E3-4246-B56C-179CC79B35D2

Q34387974-17923EBB-BBFB-4D6E-95CA-68B76147C72E

Q34387974-2B2DE47F-E402-4D30-BAD3-8B8CA024E7F4

Q34387974-403622C8-B4B0-4AD7-9C1C-8C862F95FDC8

Q34387974-520A5686-A848-4031-B85D-BFCAF8A9B270

Q34387974-77848C99-36D7-47E5-804C-9D0A2DF15AA9

Q34387974-7E6A1C45-5B57-42FF-BE7B-A015454D66DC

P304

Q34387974-95867C20-324F-4F61-9215-0E133CB133B3

P31

Q34387974-D33A65E3-E727-473B-8B65-15032285269E

P356

Q34387974-1379BB2C-762C-4778-B89A-B58E430F1852

P407

Q34387974-578B80A5-894B-42E4-BEF7-21535E9522E9

P433

Q34387974-5BBB854C-B37A-4B34-99DA-E44362EECC4B

P478

Q34387974-F084066B-54D8-45A9-8FC4-9D84BC67EAF1

P50

Q34387974-0D94122F-0606-4653-B73D-877BDEE4F153

Q34387974-3CD3CE21-8848-4E86-8ABF-A3AC610A0D36

Q34387974-7B6440EE-F735-4BF1-A343-BAD136999CE1

Q34387974-8228C7FF-693F-4EA5-BA23-FAB04FC3CDE9

Q34387974-8D031B20-8DC1-451E-84BA-B0ABF319F24B

P577

Q34387974-72D4CEA0-885C-4BBB-8CEF-821747BF292A

P5875

Q34387974-33339241-C859-42BB-8CB4-394FDC9FBCD5

P698

Q34387974-0DDF3AC6-F4A9-4769-8DF2-1A070C8E26CD

P921

Q34387974-A1E21564-91D1-4C29-A677-DD2F9A4DE9E0

P932

Q34387974-32B3A284-9AC1-42D0-952E-40AF4EE9C7CB

P356

PNAS.1320318110

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Targeting CXCL12 from FAP-expr ...... otherapy in pancreatic cancer.

@en

P2093

Andrew Deonarine

http://www.w3.org/2001/XMLSchema#string

Claire M Connell

http://www.w3.org/2001/XMLSchema#string

Derek S Chan

http://www.w3.org/2001/XMLSchema#string

Douglas T Fearon

http://www.w3.org/2001/XMLSchema#string

Duncan I Jodrell

http://www.w3.org/2001/XMLSchema#string

James O Jones

http://www.w3.org/2001/XMLSchema#string

Otavia L Caballero

http://www.w3.org/2001/XMLSchema#string

Qi Zhao

http://www.w3.org/2001/XMLSchema#string

Richard J B Wells

http://www.w3.org/2001/XMLSchema#string

Tobias Janowitz

http://www.w3.org/2001/XMLSchema#string

P2860

HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

Nivolumab plus ipilimumab in advanced melanoma.

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Active movement of T cells away from a chemokine

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

Enhancement of antitumor immunity by CTLA-4 blockade

Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion

P304

20212-20217

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1320318110

http://www.w3.org/2001/XMLSchema#string

P407

P433

50

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P50

Sarah Teichmann

Edward W Roberts

P577

2013-11-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258924056

http://www.w3.org/2001/XMLSchema#string

P698

24277834

http://www.w3.org/2001/XMLSchema#string

P921

P932

3864274

http://www.w3.org/2001/XMLSchema#string